DelveInsight’s, “Multifocal Motor Neuropathy Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Multifocal Motor Neuropathy pipeline landscape.
"Multifocal Motor Neuropathy Pipeline Insight"DelveInsight's analysis reveals several companies advancing innovative therapies in the multifocal motor neuropathy clinical pipeline, with groundbreaking ...
June 27, 2012 — Immune Globulin Infusion (Human), 10% (Gammagard Liquid, Baxter International, Inc), has been approved by the US Food and Drug Administration (FDA) as a treatment for multifocal motor ...
"The process to detect and treat Multifocal Motor Neuropathy can be lengthy and difficult, and MMN patients are often misdiagnosed, which presents additional challenges for patients experiencing ...
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Baxter International Inc. (NYSE:BAX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback